Executive or Senior Director Search

Description Summary​The Executive Director of Search & Evaluation will lead strategic sourcing and evaluation of later-stage external clinical assets in Immunology, Hematology, and Cardiovascular/Renal therapeutic areas. In addition, this role will manage all TA Leads for Early and Late Stage. These leaders will focus on opportunities from Phase 2 through marketed drugs, requiring deep clinical expertise, strong engagement with external Key Opinion Leaders (KOLs) and clinical investigators, and a keen understanding of evolving standards of care. The role is critical to shaping our portfolio through high-impact partnerships and transactions.​MainResponsibilities & Accountabilities​Lead and manage a team of early and late-stage Search & Evaluation TA Leads.​Develop the strategy and a consistent process for all Search & Evaluation activities.​Serve as the senior S&E leader within the TALT, influencing therapeutic strategy and integrating late-stage external innovation priorities into portfolio planning.​Lead proactive sourcing efforts for Phase 2 to marketed assets, identifying opportunities that align with TA strategy and unmet medical needs.​Co-lead internal meetings (with Early Search Lead) focused on evaluating and prioritizing New Product Opportunities (NPOs) within each CSL’s therapeutic areas. NPO meetings are strategic checkpoints where cross-functional teams review potential assets identified by Search and decide whether to advance them for further due diligence and deal negotiations​Engage extensively with external KOLs, clinical investigators, and networks to validate asset potential, understand trial designs & clinical endpoints, and anticipate competitive dynamics.​Maintain deep awareness of changing standards of care and competitive landscapes to inform sourcing priorities and deal strategy.​Drive cross-functional due diligence for late-stage assets, coordinating clinical, regulatory, commercial, and market access assessments to support governance decisions.​Partner closely with BD and Regional Ecosystem Leads to advance high-priority opportunities through negotiation and deal close, ensuring seamless handoff and execution​Represent the TA externally, leading sourcing activities at specialized conferences and building relationships with pharma, biotech, and clinical communities.​Qualifications & Experience Requirements​15+ years in biopharma with significant experience in clinical development, external innovation, or business development.​Advanced degree required (MD, PhD, or equivalent).​Deep clinical expertise in Immunology, Hematology, or Cardiovascular/Renal therapeutic areas.​Proven track record of sourcing and closing late-stage deals and engaging with KOLs and clinical networks.​Strong understanding of regulatory pathways, market access, and competitive standards of care.​Experience leading a global team​#LI-HYBRIDAbout CSL BehringCSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL, headquartered in Melbourne, Australia, employs 32,000 people, and delivers its lifesaving therapies to people in more than 100 countries.To learn more about CSL, CSL Behring, CSL Seqirus and CSL Vifor visit and CSL Plasma at .Our Benefits